Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

72.83 +2.61 (+3.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
News headline image
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying. ↗
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
News headline image
(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark ↗
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
News headline image
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective. ↗
There are signs that NASDAQ:HALO may be ready to breakout. 
Via Chartmill
News headline image
NASDAQ:HALO is showing good growth, while it is not too expensive. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition ↗
These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. 
Via InvestorPlace
News headline image
Biotech Arvinas Stock Earns 82 RS Rating ↗
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
News headline image
Denali Therapeutics Stock Gets Technical Rating Upgrade ↗
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Buy Now: Q3 Edition ↗
Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry. 
Via InvestorPlace
News headline image
NASDAQ:HALO qualifies as a high growth stock and is consolidating. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
NASDAQ:HALO Shows Potential for a Breakout. ↗
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective. 
Via Chartmill
News headline image
Decoding 12 Analyst Evaluations For Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
NASDAQ:HALO: a strong growth stock preparing for the next leg up?. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
3 Highly Rated Biotech Stocks for Your July Buy List ↗
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. 
Via InvestorPlace
News headline image
3 Breakout Biotech Stocks on Track to Double by 2032 ↗
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify. 
Via InvestorPlace
News headline image
UroGen Pharma Stock Earns 91 RS Rating ↗
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
News headline image
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗
Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO). 
Via Chartmill
News headline image
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval ↗
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier. 
Via Investor's Business Daily
News headline image
Arcellx Stock Earns Relative Strength Rating Upgrade ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
News headline image
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
The 3 Best Healthcare Stocks to Buy in June 2024 ↗
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on. 
Via InvestorPlace
News headline image
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
News headline image
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.